Oxidative stress in NPC1 deficient cells: protective effect of allopregnanolone
Stefania Zampieri
Unita di Malattie Metaboliche, IRCCS Burlo Garofolo, Trieste, Italy
Search for more papers by this authorSynthia H. Mellon
Department of Obstetrics, Gynecology and Reproductive Sciences, The Center for Reproductive Sciences, University of California, San Francisco, CA, USA
Search for more papers by this authorTerry D. Butters
Department of Biochemistry, University of Oxford, Oxford, United Kingdom
Search for more papers by this authorMarco Nevyjel
Unita di Malattie Metaboliche, IRCCS Burlo Garofolo, Trieste, Italy
Search for more papers by this authorDouglas F. Covey
Department of Developmental Biology, Washington University in St. Louis, School of Medicine, St. Louis, MO, USA
Search for more papers by this authorCorresponding Author
Bruno Bembi
Unita di Malattie Metaboliche, IRCCS Burlo Garofolo, Trieste, Italy
Regional Coordinator Centre for Rare Diseases, University Hospital “Santa Maria della Misericordia”, Udine, Italy
Correspondence to: Dr. Bruno BEMBI, Coordinator Centre for Rare Diseases, University Hospital “Santa Maria della Misericordia”, Piazzale Santa Maria della Misericordia 15, 33100, Udine, Italy.Tel.: +39 0432559914Fax: +39 04325544617E-mail: [email protected]Search for more papers by this authorAndrea Dardis
Unita di Malattie Metaboliche, IRCCS Burlo Garofolo, Trieste, Italy
Search for more papers by this authorStefania Zampieri
Unita di Malattie Metaboliche, IRCCS Burlo Garofolo, Trieste, Italy
Search for more papers by this authorSynthia H. Mellon
Department of Obstetrics, Gynecology and Reproductive Sciences, The Center for Reproductive Sciences, University of California, San Francisco, CA, USA
Search for more papers by this authorTerry D. Butters
Department of Biochemistry, University of Oxford, Oxford, United Kingdom
Search for more papers by this authorMarco Nevyjel
Unita di Malattie Metaboliche, IRCCS Burlo Garofolo, Trieste, Italy
Search for more papers by this authorDouglas F. Covey
Department of Developmental Biology, Washington University in St. Louis, School of Medicine, St. Louis, MO, USA
Search for more papers by this authorCorresponding Author
Bruno Bembi
Unita di Malattie Metaboliche, IRCCS Burlo Garofolo, Trieste, Italy
Regional Coordinator Centre for Rare Diseases, University Hospital “Santa Maria della Misericordia”, Udine, Italy
Correspondence to: Dr. Bruno BEMBI, Coordinator Centre for Rare Diseases, University Hospital “Santa Maria della Misericordia”, Piazzale Santa Maria della Misericordia 15, 33100, Udine, Italy.Tel.: +39 0432559914Fax: +39 04325544617E-mail: [email protected]Search for more papers by this authorAndrea Dardis
Unita di Malattie Metaboliche, IRCCS Burlo Garofolo, Trieste, Italy
Search for more papers by this authorAbstract
Niemann-Pick C disease (NPC) is an autosomal recessive neurodegenerative disorder caused by the abnormal function of NPC1 or NPC2 proteins, leading to an accumulation of unesterified cholesterol and glycosphingolipids (GSLs) in the lysosomes. The mechanisms underlying the pathophysiology in NPC disease are not clear. Oxidative damage is implicated in the pathophysiology of different neurological disorders and the effect of GSL accumulation on the intracellular redox state has been documented. Therefore, we determined whether the intracellular redox state might contribute to the NPC disease pathophysiology. Because the treatment of NPC mice with allopregnanolone (ALLO) increases their lifespan and delays the onset of neurological impairment, we analysed the effect of ALLO on the oxidative damage in human NPC fibroblasts. Concentrations of reactive oxygen species (ROS) and lipid peroxidation were higher in fibroblasts from NPC patients than in fibroblasts from normal subjects. Fibroblasts from NPC patients were more susceptible to cell death through apoptosis after an acute oxidative insult. This process is mediated by activation of the NF-κB signalling pathway. Knockdown of NPC1 mRNA both in normal fibroblasts and in human SH-SY5Y neuroblastoma cells caused increased ROS concentrations. ALLO treatment of fibroblasts from NPC patients or NPC1 knockdown cells reduced the levels of ROS and lipid peroxidation and prevented peroxide-induced apoptosis and NF-kB activation. Thus, these findings suggest that oxidative stress might contribute to the NPC disease and ALLO might be beneficial in the treatment of the disease, at least in part, due to its ability to restore the intracellular redox state.
References
- 1 Patterson MC, Vanier MT, Suzuki K, et al. Niemann Pick disease type C: a lipid trafficking disorder. In: CR Scriver, AL Beaudet, WS ly, D Valle, editors. The metabolic and molecular basis of inherited diseases. New York : Mc Graw-Hill ; 2001. pp. 3611–34.
- 2 Vanier MT, Millat G. Niemann Pick disease type C. Clin Genet. 2003; 64: 69–81.
- 3 Steinberg SJ, Ward CP, Fensom AH. Complementation studies in Niemann-Pick disease type C indicate the existence of a second group. J Med Genet. 1994; 31: 317–20.
- 4 Vanier MT, Duthel S, Rodriguez-Lafrasse C, et al. Genetic heterogeneity in Niemann-Pick C disease: a study using somatic cell hybridization and linkage analysis. Am J Hum Genet. 1996; 58: 118–25.
- 5 Carstea ED, Morris JA, Coleman KG, et al. Niemann-Pick C1 disease gene: homology to mediators of cholesterol homeostasis. Science. 1997; 277: 228–31.
- 6 North S, Moenner M, Bikfalvi A. Recent developments in the regulation of the angiogenic switch by cellular stress factors in tumors. Cancer Lett. 2005; 218: 1–14.
- 7 Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001; 414: 813–20.
- 8 Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest. 1993; 91: 2546–51.
- 9 Culmsee C, Landshamer S. Molecular insights into mechanisms of the cell death program: role in the progression of neurodegenerative disorders. Curr Alzheimer Res. 2006; 3: 269–83.
- 10 Napoli C, Palinski W. Neurodegenerative diseases: insights into pathogenic mechanisms from atherosclerosis. Neurobiol Aging. 2005; 26: 293–302.
- 11 Deganuto M, Pittis MG, Pines A, et al. Altered intracellular redox status in Gaucher Disease fibroblasts and impairment of adaptive response against oxidative stress. J Cell Physiol. 2007; 212: 223–35.
- 12 Sparrow SM, Carter JM, Ridgway ND, et al. U18666A inhibits intracellular cholesterol transport and neurotransmitter release in human neuroblastoma cells. Neurochem Res. 1999; 24: 69–77.
- 13 Koh CH, Whiteman M, Li QX, et al . Chronic exposure to U18666A is associated with oxidative stress in cultured murine cortical neurons. J Neurochem. 2006; 98: 1278–89.
- 14 Griffin LD, Gong W, Verot L, et al. Niemann-Pick type C disease involves disrupted neurosteroidogenesis and responds to allopregnanolone. Nat Med. 2004; 10: 704–11.
- 15 Langmade SJ, Gale SE, Frolov A, et al. Pregnane X receptor (PXR) activation: a mechanism for neuroprotection in a mouse model of Niemann-Pick C disease. Proc Natl Acad Sci USA. 2006; 103: 13807–12.
- 16 Wittmer LL, Hu Y, Kalkbrenner M, et al. Enantioselectivity of steroid-induced gamma-aminobutyric acidA receptor modulation and anesthesia. Mol Pharmacol. 1996; 50: 1581–6.
- 17 Alakoskela JM, Covey DF, Kinnunen PKJ. Lack of enantiomeric specificity in effects of anesthetic steroids on lipid bilayers. Biochim Biophys Acta. 2007; 1768, 131–45.
- 18
Frenkel K,
Gleichauf C.
Hydrogen peroxide formation by cells treated with a tumor promoter.
Free Radic Res Commun.
1991; 2: 783–94.
10.3109/10715769109145860 Google Scholar
- 19 Yeh S, Hu M. Antioxidant and pro-oxidant effects of lycopene in comparison with beta-carotene on oxidant-induced damage in Hs68 cells. J Nutr Biochem. 2000; 11: 548–54.
- 20 Blois MS. Antioxidant determination by use of a stable free radical. Nature. 1958; 29: 248–54.
- 21 Koopman G, Reutelingsperger CP, Kuijten GA, et al. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood. 1994; 84: 1415–20.
- 22 Blanchette-Mackie EJ, Dwyer NK, Amende LM, et al. Type-C Niemann-Pick disease: low density lipoprotein uptake is associated with premature cholesterol accumulation in the Golgi complex and excessive cholesterol storage in lysosomes. Proc Natl Acad Sci USA. 1988; 85: 8022–6.
- 23 Svennerholm L, Fredman P. A procedure for the quantitative isolation of brain gangliosides. Biochim Biophys Acta. 1980; 617: 97–109.
- 24 Neville DC, Coquard V, Priestman DA, et al . Analysis of fluorescently labeled glycosphingolipid-derived oligosaccharides following ceramide glycanase digestion and anthranilic acid labeling. Anal Biochem. 2004; 331: 275–82.
- 25 Kaltschmidt B, Sparna T, Kaltschmidt C. Activation of NF-kB by reactive oxigen intermediates in the nervous system. Antioxid Redox Signal. 1999; 1: 129–44.
- 26 Vollgraf U, Wegner M, Richter-Landsberg C. Activation of AP-1 and nuclear factor-kB transcription factors is involved in hydrogen peroxide-induced apoptotic cell death of oligodendrocytes. J Neurochem. 1999; 73: 2501–19.
- 27 Reddy JV, Ganley IG, Pfeffer SR. Clues to neuro-degeneration in Niemann-Pick Type C disease from global gene expression profiling. PloS One. 2006; 20: 1: e19.
- 28 Schedin S, Sindelar PJ, Pentchev P, et al. Peroxisomal impairment in Niemann-Pick type C disease. J Biol Chem. 1997; 272: 6245–51
- 29 Majewska MD, Harrison NL, Schwartz RD, et al. Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. Science. 1986; 232: 1004–7.
- 30 Mellon SH, Griffin LD. Neurosteroids: biochemistry and clinical significance. Trends Endocrinol Metab. 2002; 13: 35–43.
- 31 Kousteni S, Bellido T, Plotkin L, et al. Non-genotropic, sex non-specific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell. 2001; 104: 719–30.
- 32 Kelly M, Levin E. Rapid actions of plasma membrane estrogen receptors. Trends Endocrinol Metab. 2001; 12: 152–6.
- 33 Levin ER. Cellular functions of plasma membrane estrogen receptors. Steroids. 2002; 67: 471–5.
- 34 Hammes SR, Levin ER. Extranuclear steroid receptors: nature and actions. Endocr Rev. 2007; 28: 726–41.
- 35 Kampa M, Castanas E. Membrane steroid receptor signaling in normal and neoplastic cells. Mol Cell Endocrinol. 2006; 246: 76–82.
- 36 Behl C. Estrogen can protect neurons: modes of action. J Steroid Biochem Mol Biol. 2002; 83: 195–7.
- 37 Prokai L, Prokai-Tatrai K, Perjesi P, et al. Quinol-based cyclic antioxidant mechanism in estrogen neuroprotection. Proc Natl Acad Sc. USA. 2003; 100: 11741–6.
- 38 Michiels C, Minet E, Mottet D, et al. Regulation of gene expression by oxigen: NF-kB and HIF-1, two extremes. Free Radic Biol Med. 2002; 33: 1231–42.
- 39 Marx CE, Trost WT, Shampine LJ, et al. The Neurosteroid allopregnanolone is reduced in prefrontal cortex in Alzheimer’s disease. Biol Psychiatry. 2006; 60: 1287–94.
- 40 Smith CD, Wekstein DR, Markesbery WR, et al. 3alpha,5alpha-THP: a potential plasma neurosteroid biomarker in Alzheimer’s disease and perhaps non-Alzheimer’s dementia. Psychopharmacology. 2006; 186: 481–5.
- 41 Sultana R, Perluigi M, Butterfield DA. Protein oxidation and lipid peroxidation in brain of subjects with Alzheimer’s disease: insights into mechanism of neurodegeneration from redox proteomics. Antioxid Redox Signal. 2006; 8: 2021–37.
- 42 Brinton RD, Wang JM. Preclinical analyses of the therapeutic potential of allopregnanolone to promote neurogenesis in vitro and in vivo in transgenic mouse model of Alzheimer’s disease. Curr Alzheimer Res. 2006; 3: 11–7.
- 43 Brinton RD, Wang JM. Therapeutic potential of neurogenesis for prevention and recovery from Alzheimer’s disease: allopregnanolone as a proof of concept neurogenic agent. Curr Alzheimer Res. 2006; 3: 185–90.
- 44 Ahmad I, Lope-Piedrafita S, Bi X, et al. Allopregnanolone treatment, both as a single injection or repetitively, delays demyelination and enhances survival of Niemann-Pick C mice. J Neurosci Res. 2005; 82: 811–21.